HBOT Conversations:
Laurie Anderson (Part 2)
Healing COVID with HBOT
Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF). Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center. For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.
Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing. She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health. Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach. She discovered HBOT when she was struggling to heal from COVID, and now tells anyone who will listen about the power of oxygen and pressure.
Watch the Podcast
We continue Dr. Laurie Anderson’s HBOT News Network interview, diving in deeper to Hyperbaric Oxygen Therapy to heal COVID, and we bring up her struggles with Lyme Disease. Her interview is being released as a three part series, with Part 1 being released last week.
This podcast starts with our host, Ed di Girolamo, explaining to the audience that he and Dr. Laurie had a brief conversation before the interview, and they discussed autoimmune diseases, or the mechanisms of autoimmune diseases, that would include inflammation or hypoxia. He askes Dr. Laurie if this was discussed in her schooling when she got her doctorate in pharmacology. She explained that it was certainly talked about, but she really started to understand the trajectory of an underlying inflammatory process when she got sick. To help her heal, she applied her own medical knowledge to her healing process, and explains —
“But that wasn’t a cornerstone of what we learned, and it really became a cornerstone of my own healing, that getting control of inflammation was the way that my immune system was going to ramp back up and that my body was going to heal, unequivocally. It was all about addressing that inflammation.”
di Girolamo explains that years ago he attended a medical conference in Albuquerque that was specific to hyperbaric oxygen therapy, and he was on the edge of his seat for all three days. It was then that he started to truly understand how to read the science of HBOT. He brings up Lyme disease, which Dr. Laurie has personally struggled with, and recalls that there was a group of people there who have done HBOT and we’re so passionate in pushing it to help with Lyme disease because hyperbarics helped them, and they believe in it. di Girolamo states that through speaking to the medical profession about HBOT and Lyme, he has learned that Lyme disease is a virus and by doing a certain protocol of HBOT you’re essentially feeding the virus so much oxygen that it basically can not survive anymore and you “drown it”.
As the conversation progresses about Lyme disease, Dr. Laurie lists some symptoms and how HBOT helped her with tremendously with sleeping. After her first treatment she slept for 12 hours, which was unheard of for her. And she recalls that it was a very deep and refreshing sleep. She struggled for years and years with sleep from Lyme disease. Back then, HBOT was on the table as an alternative method of healing but she was only introduced to the mono-chambers and due to her extreme claustrophobia, it was not a healing avenue she wanted to explore at that time. She is thankful for the large multi-place chambers at Extivita that allowed Dr. Laurie to take a leap of faith and finally try HBOT.
Dr. Laurie’s career involves her reviewing the safety of clinical trials daily, so she explains that in order for a trial or study to be safe and effective, dosage is critical. di Girolamo explained that it’s the same for HBOT…. the right dosage of oxygen + pressure is critical to having healing success. He mentioned the podcasts with Dr. Stevens & Dr. Harch, as they both spoke in depth about dosage for hyperbaric oxygen therapy, especially for the indications that are considered to be “off label” for treatment with HBOT. Every person is unique and what works for one might not work the same for the next, so dosage can be tricky. But, in the end di Girolamo explains —
“I think at least in my conclusion, my humble opinion, is that any hyperbaric oxygen is better than no hyperbaric oxygen.”
Dr. Laurie referred to HBOT as a gift, because all that oxygen does so much for your brain. Which is exactly where it’s been proven to help veterans heal from PTSD, depression, anxiety, and even TBIs. She stresses that the mind-body connection is so strong, but it’s not talked about like it should be. In her opinion, she thinks that all that oxygen is strengthening the mind-body connection to the point where the brain is receiving that surge of oxygen and basically then signal the body that it’s ok…. let’s heal.
Stay tuned next week for Part 3 of Dr. Laurie’s podcast.
Guests
Dr. Laurie Anderson, Pharm.D.
Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing. She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health. Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach.
When not working, Dr. Laurie is an avid gardener, ballroom dancer and traveler with her husband. Remaining curious and finding joy in every day are her super powers.
Subscribe Now, It’s Free!
Recent HBOT News
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn’s disease.
Fistulizing Crohn’s disease (CD) presents a therapeutic challenge as fistulae are notoriously difficult to heal. Mycobacterium avium ss paratuberculosis (MAP) treatment in CD is gaining attention. We evaluated healing of CD fistula(e) using a novel combination therapy. Nine consecutive patients who failed to heal fistulae on conventional treatment including anti-TNF, were treated with at least three doses of infliximab, 18-30 courses of hyperbaric oxygen therapy and anti-MAP antibiotics comprising rifabutin, clarithromycin and clofazimine. All patients achieved complete healing of fistulae by 6-28 weeks and follow-up for mean 18 months.
Clinical Trial – Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery
Regional anesthesia has become more popular in cesarean deliveries because most of the
parturients prefer being awake during the birth process. In addition, regional anesthesia may
be a safer method than general. In spinal anesthesia local anesthetics alone may not be
enough for an effective postoperative analgesia and hemodynamic stability of the patient wich
is crucial during cesarean section. So far many adjuvants have been used to augment the
analgesia produced by intrathecal local anesthetics and to reduce their adverse effects .
Various intrathecal adjuvants to local anaesthetics have found to improve the quality and
extend duration of spinal block. Prolongation of duration of spinal block is desirable both
for long procedures and for postoperative pain relief. Efficacy and safty of intrathecal
magnesium as analgesic adjuvant has been tested by several clinical trails in recent
years.Antinociceptive effect of magnesium appears to be relevant for the management of
chronic and post operative pain. These effects are primarily based on regulation of calcium
influx in to the cell. Magnesium blocks calcium influx and non competitively antagonizes NMDA
channels. NMDA receptor signelling plays an impartent in determining the duration of acute
pain3).) addition of magnesium to spinal anaesthesia improved postoperative analgesia in
orthopedic setting. addition of intrathecal magnesium sulfate to 10 mg bupivacaine plus 25µg
fentanyl prolonged spinal anaesthesia in patients undergoing lower extremity surgery.
Dexmedetomidine is a highly selective 2-adrenergic agonist which has been used as
pre-medication and as an adjuvant to general anesthesia.Dexmedetomidine have several
beneficial actions during perioperative period. They decrease sympathetic tone with
attenuation of the neuroendocrine and haemodynamic response to anaesthesia and surgery,
reduce anaesthetic and opiod requirement, cause sedation and analgesia. Dexmedetomidine was
first introduced into clinical practice as a short term intravenous sedative in intensive
care. Like any other adjuvant dexmedetomidine is not free from adverse effects. Use of
dexmedetomidine is often associated with a decrease in heart rate and blood
pressure.Dexmedetomidine was used to enhance the analgesic property of local anaesthetics
like lidocaine bupivacaine and ropivacaine. In vivo and in vitro studies indicated that these
local anaesthetics had significant neurotoxicity. Dexmedetomidine showed protective or growth
promoting properties in tissues, including nerve cells from cortex. Intrathecal
dexmedetomidine has a neuroprotective effect similar to methylprednisolone.
The mechanism by which intrathecal alpha 2-adrenergic agonists prolong the motor and sensory
block of local anesthetics is not clear. It may be an additive or synergistic effect
secondary to the different mechanisms of action of local anesthetic and alpha 2 adrenergic
agonist. The local anesthetics act by blocking sodium channels, whereas the alpha 2
adrenergic agonist acts by binding to pre synapyic C fibre and post synaptic dorsal horn
neurons. Intrathecal alpha 2 adrenergic agonist produce analgesia by depressing the realease
of C fibre transmission by hyperpolarization of post synaptic dorsal horn neurons. Li et al
observed that Glutamate is involved in excitatory neurotransmission nociception and plays an
essential role in relaying noxious stimuli in the spinal cord. Intrathecal injection of alpha
2 adrenergic agonists produces potent antinociceptive effects by altering spinal
neurotransmitter release and effectively treats acute pain.
Efficacy of hyperbaric oxygen therapy combined with mild hyperthermia for improving the anti-tumour effects of carboplatin.
Abstract: The aim of this study was to evaluate the effects of hyperbaric oxygen therapy (HBO) on the enhancement of hyperthermic chemosensitisation to carboplatin at mild temperatures in experimental tumours. SCCVII carcinoma in C3H/He mice was used to assess tumour...